0
Deep & Emerging Tech·April 17, 2026·1 min read

Revolution Medicines' buyout price soars after pancreatic cancer win

Share

Revolution’s rumored $30B buyout talk before data versus its post–Phase 3 leverage now is the clearest signal: in oncology, late-stage clinical proof is the real valuation driver, not strategic speculation. If you’re a BD lead, you either pay up post-readout or take real risk earlier—there’s no more cheap optionality once survival curves are public.

Deep & Emerging Tech

Cisco tells Webex users to patch critical security flaws immediately, as experts find its Wi-Fi boxes may be filling their disks with undeletable data every day

Four critical Webex flaws plus Wi‑Fi APs quietly filling disks with undeletable data is a reminder that collaboration and network gear are now continuous security programs, not set-and-forget capex. If you run IT, treat vendor patch cycles as part of your operational rhythm — and audit what telemetry your boxes are actually storing.